Drug Trial Radar · NCT06877650
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
436
Planned (sponsor's estimate)
Start
Apr 11, 2025
Primary completion
Mar 30, 2028
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.
Conditions
- Advanced Malignant Tumors
Interventions
JMT108Drug
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
PembrolizumabDrug
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
IvonescimabDrug
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity(DLT)Time frame: Approximately 28 days.
- Adverse Events (AEs)Time frame: through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.